Asimov is building tools to program living cells using synthetic biology. Nature has evolved billions of molecular tools in the form of genes that can now be cataloged, refined and remixed using synthetic biology to build new biological systems. Asimov is capitalizing on this approach using their mammalian cell engineering platform to advance the manufacture of biologics like monoclonal antibodies and multifunctional proteins and the design of gene therapies. The platform uses computer-aided design, simulation and debugging of genetic systems, cell lines for manufacturing and a genetic parts database for custom functionality. Computational modeling is critical for Asimov to move synthetic biology beyond traditional screening and unlock an unbounded design space.

<p>Asimov is building tools to program living cells using synthetic biology. Nature has evolved billions of molecular tools in the form of genes that can now be cataloged, refined and remixed using synthetic biology to build new biological systems. Asimov is capitalizing on this approach using their mammalian cell engineering platform to advance the manufacture of biologics like monoclonal antibodies and multifunctional proteins and the design of gene therapies. The platform uses computer-aided design, simulation and debugging of genetic systems, cell lines for manufacturing and a genetic parts database for custom functionality. Computational modeling is critical for Asimov to move synthetic biology beyond traditional screening and unlock an unbounded design space.</p>


Asimov

Founded: 2017
Location: Boston, MA
Employee range: 11 - 50
Funding: $175M B Jan 2023
Investors: CPP Investment Board, Fidelity Management &amp; Research, Casdin Capital, KdT Ventures

About:

Jobs: